International Journal of Medical and Biomedical Studies · 2019 · 11 citations · 0 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsBlood-brain Barrier PenetrationBlood-brain Barrier PharmacologyBlood-brain Barrier ToxicityGlioblastomaOncology PharmacologyStructure-activity Relationship AnalysisAnticancer ActivityBlood-brain Barrier PermeabilityCytotoxicity Assays
In design of new CNS drugs, profound and selective cytotoxicity, penetration through the blood brain barrier along with lack of neurotoxic effects coupled with no side effects in humans at a dose of 3 mg/kg administered actually make the avarol chemical scaffold (Figure 1) an ideal candidate [1]. This study aimed to screen in vitro structure-activity relationship (along with selectivity) using avarol (followed by its structural elements) and the human malignant glioma U-251 MG cells